DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20150090

The effect of misoprostol on intraoperative blood loss after myomectomy

Mansoureh Vahdat, Maryam Kashanian, Sara Asadollah, Payman Yazdkhasti, Nasrin Nikravan

Abstract


Background: Uterine myomas are common benign tumors in the reproductive period. Bleeding during myomectomy is one of the major complications. We designed a randomized clinical trial to investigate the effectiveness of misoprostol on reducing Intraoperative Blood Loss (IBL) after myomectomy.

Methods: Sixty four patients undergoing abdominal myomectomy were randomized into misoprostol group (n=32) that were given 200 micrograms sublingual misoprostol 0.5 hour before the operation and control group (n=32) that were given placebo. Hemoglobin (Hb) was recorded preoperative, 6 h and 24 h after surgery. Data were analyzed by SPSS software (V.20).

Results: Mean of age, body mass index and baseline Hb were not statistically significant between the groups however Hb in 6h after operation were significantly higher in misoprostol group but not significant after 24 h (Hb 6h: 9.8 ±0.8 vs. 9.1 ± 0.9, P=0.003 and Hb 24 h: 10.50 ± 0.56 vs. 10.24 ± 0.58, P=0.066). No difference was observed in terms of anemia and need for blood transfusion after operation among the groups.  

Conclusions: Preoperative use of sublingual misoprostol is effective in reducing IBL for women undergoing myomectomies in short time (after 6 h). Further studies should be performed to investigate the effectiveness of preoperative misoprostol with various routes and doses in other post-operative time on reducing IBL in abdominal myomectomy. 


Keywords


Misoprostol, Myomectomy, Intraoperative blood loss

Full Text:

PDF

References


Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981 Oct;36(4):433-45.

Parker WH. Uterine myomas: management. Fertil Steril. 2007 Aug;88(2):255-71.

LaMorte AI, Lalwani S, Diamond MP. Morbidity associated with abdominal myomectomy. Obstet Gynecol. 1993 Dec;82(6):897-900.

Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;(2):CD000547.

Liu W, Tzeng C, Yi-Jen C, Wang P. Combining the uterine depletion procedure and myomectomy may be useful for treating symptomatic fibroids. Fertil Steril. 2004 Jul;82(1):205-10.

Ngeh N, Belli A, Morgan R, Manyonda I. Pre-myomectomy uterine embolization minimizes operative blood loss. BJOG. 2004 Oct;111(10):1139-40.

Chang FW, Yu MH, Ku CH, Chen CH, Wu GJ, Liu JY. Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy: a randomised controlled trial. BJOG. 2006 Jan;113(1):47-52.

Celik H, Sapnaz E. Use of a single preoperative dose misoprostol is efficacious for patients who undergo abdominal myomectomy. Fertil Steril. 2003 May;79(5):1207-10.

Wray S. Uterine contraction and physiological mechanisms of modulation. Am J Physiol. 1993 Jan;264(1 Pt 1):1-18.

Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol. 2004 May;103(5 Pt 1):866-70.

Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002 Feb;17(2):332-6.

Naib JM, Naveed P, Fatima S. Pre-operative use of misoprostol in major gynaecological surgeries. J Med Sci. 2013;21(4):171-3.

Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007 Dec;99(2):160-7.

Allen R, M O’Brien B. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2(3):159-68.